European regulators have recommended expanding use of the IL-23 inhibitor Skyrizi to treat moderate-to-severe plaque psoriasis in children aged 6 years or older who require systemic therapy.

April 27 (Reuters) - Oruka Therapeutics said on Monday that interim results showed its experimental drug helped clear psoriasis within 16 weeks, meeting the main goal of a mid-stage study and sending ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Picankibart is a recombinant anti-interleukin 23p19 ...

Botulinum toxin A (BoNT-A) exhibited promising results for nail psoriasis for up to 6 months with a single injection. Botulinum toxin A (BoNT-A) injection emerged as an effective therapy for patients ...

Emerging research presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting is reinforcing a critical shift ...

At the recent American Academy of Dermatology (AAD) annual meeting, new phase III data from the LATITUDE-PsO-3001 and ...

Please provide your email address to receive an email when new articles are posted on . A 2.5 mg/mL dose of triamcinolone acetonide showed equally as efficacious treatment for nail psoriasis vs.

The webinar will be broadcast via Zoom. Interested participants can register using the following LINK. The discussion will provide an in-depth exploration of the plaque psoriasis landscape, current ...

NEW YORK (Reuters Health) - Injections of a protein called interleukin-4 (IL-4) seem equal to the best therapy now available for relieving symptoms of the chronic skin condition psoriasis, the results ...

Despite recent significant advances in systemic therapies for psoriasis, topical treatment retains a prominent role for many patients. The American Academy of Dermatology/National Psoriasis Foundation ...